PARKS: Well, that's what I was going to ask because the pathogen access and benefit sharing seems to be, to me, one of the most interesting parts of this treaty because I know in the past - right? - countries have had an issue with sort of giving up information on pathogens and not feeling like they were then rewarded or something with access to the medicines that came from giving that information. Can you explain that a little bit more?